STOCK TITAN
  1. Home
  2. Sec-filings
  3. GALT
  4. [Form 4/A] GALECTIN THERAPEUTICS INC Amended Insider Trading Activity

Galectin Therapeutics (GALT) CEO awarded 91,000 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Galectin Therapeutics Inc. reported an amended insider transaction for its President, CEO and director, Jack W. Callicutt. On January 16, 2026, he was granted a stock option to buy 91,000 shares of common stock at an exercise price of $3.04 per share under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

The option vests in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expires on January 16, 2036. Following this grant, Callicutt directly holds 91,000 derivative securities in the form of these options. This Form 4/A corrects the originally filed number of options previously reported on January 21, 2026.

Positive

  • None.

Negative

  • None.
Insider LEWIS JOEL
Role President and CEO
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 91,000 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 91,000 shares (Direct)
Footnotes (1)
  1. Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. The original Form 4 filed had an incorrect number of common stock options. This amendment presents the correct number of common stock options granted.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEWIS JOEL
(Last) (First) (Middle)
C/O GALECTIN THERAPEUTICS INC.
4960 PEACHTREE INDUSTRIAL BLVD., STE 240
(Street)
NORCROSS GA 30071
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
01/21/2026 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy)(1) $3.04 01/16/2026 A 91,000(3) (2) 01/16/2036 Common Stock 91,000 $0 91,000 D
Explanation of Responses:
1. Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
2. The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.
3. The original Form 4 filed had an incorrect number of common stock options. This amendment presents the correct number of common stock options granted.
Jack W. Callicutt 01/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Galectin Therapeutics (GALT) disclose in this Form 4/A?

The filing reports an amended insider transaction showing that President, CEO and director Jack W. Callicutt received a grant of 91,000 stock options in Galectin Therapeutics Inc.

How many Galectin Therapeutics (GALT) stock options were granted to Jack W. Callicutt?

Jack W. Callicutt was granted 91,000 stock options, each exercisable for one share of Galectin Therapeutics common stock at an exercise price of $3.04 per share.

What is the vesting schedule for the 91,000 Galectin Therapeutics (GALT) stock options?

The options vest in four equal 25% tranches on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.

When do Jack W. Callicutt’s Galectin Therapeutics (GALT) stock options expire?

The stock options granted to Jack W. Callicutt expire on January 16, 2036, giving him the right to purchase common shares until that date at $3.04 per share.

Under which plan were the Galectin Therapeutics (GALT) options granted?

The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, as noted in the explanation of responses.

Why is this Galectin Therapeutics (GALT) Form 4 an amendment?

This is an amendment because the original Form 4 filed on January 21, 2026 reported an incorrect number of common stock options; this Form 4/A presents the correct 91,000-option grant.

Does Jack W. Callicutt hold these Galectin Therapeutics (GALT) options directly or indirectly?

The filing shows that the 91,000 stock options are held with direct ownership by Jack W. Callicutt.